Literature DB >> 9010911

Interaction between CD44 and osteopontin as a potential basis for metastasis formation.

G F Weber1, S Ashkar, H Cantor.   

Abstract

Malignant growth has been associated with oncogene activation, telomerase activity, and expression of CD44 splice variants on the cell surface. Though dysregulation of growth control due to expression of oncogene products is fairly well understood, the mechanism of CD44-mediated homing and colony formation in specific tissues has remained cryptic. We have identified the cytokine osteopontin as a ligand for CD44. Osteopontin binds to naturally expressed and stably transfected CD44 in a manner that is specific, dose-dependent, inhibitable by anti-CD44 antibodies, insensitive to competition by Gly-Arg-Gly-Asp-Ser, and sensitive to competition by hyaluronate. The receptor-ligand interaction mediates chemotaxis or attachment, depending on presentation of osteopontin in soluble or immobilized form. In contrast, binding of CD44 to hyaluronate mediates aggregation or attachment but not chemotaxis. We found that two events occurring in malignancy-secretion of osteopontin and expression of CD44v-are linked in such a way that they may cause migration of tumor cells to specific sites of metastasis formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010911

Source DB:  PubMed          Journal:  Proc Assoc Am Physicians        ISSN: 1081-650X


  32 in total

Review 1.  The biology of head and neck cancer stem cells.

Authors:  Zhaocheng Zhang; Manoel Sant'Ana Filho; Jacques E Nör
Journal:  Oral Oncol       Date:  2011-11-08       Impact factor: 5.337

Review 2.  The Rho GTPase signalling pathway in urothelial carcinoma.

Authors:  Solomon L Woldu; Ryan C Hutchinson; Laura-Maria Krabbe; Oner Sanli; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

3.  Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.

Authors:  Renee J Phillips; Karla J Helbig; Kylie H Van der Hoek; Devanshi Seth; Michael R Beard
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

4.  An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.

Authors:  Mansoor Ahmed; Joseph L Sottnik; Garrett M Dancik; Divya Sahu; Donna E Hansel; Dan Theodorescu; Martin A Schwartz
Journal:  Cancer Cell       Date:  2016-09-01       Impact factor: 31.743

5.  Lipid raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration.

Authors:  Simona Donatello; Irina S Babina; Lee D Hazelwood; Arnold D K Hill; Ivan R Nabi; Ann M Hopkins
Journal:  Am J Pathol       Date:  2012-09-29       Impact factor: 4.307

6.  Involvement of osteopontin as a core protein in craniopharyngioma calcification formation.

Authors:  SongTao Qi; GuangLong Huang; Jun Pan; Jia Li; Xi'An Zhang; LuXiong Fang; BaoGuo Liu; Wei Meng; YongMing Zhang; XiaoJun Liu
Journal:  J Neurooncol       Date:  2009-11-10       Impact factor: 4.130

7.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

Review 8.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

9.  Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer.

Authors:  Wang Likui; Wang Hong; Zhang Shuwen
Journal:  J Gastrointest Surg       Date:  2009-09-18       Impact factor: 3.452

10.  Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells.

Authors:  Brian W Robertson; Meenakshi A Chellaiah
Journal:  Exp Cell Res       Date:  2009-10-20       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.